|Bulletin Board Archived Bulletin Board About John Latest Ideas Symptoms Tests and Drugs Weight Loss Experiment Hyperthyroidism Hypothyroidism Supplement List Medical Science Heredity Other Diseases Thyroid Physiology Deeper Studies Nutrients and Toxics Hair Analysis Book Reports Glossary Table of Contents||
Older Women on Estrogen at Increased Risk for Needing Gall Bladder or Appendix RemovedTORONTO, ON -- May 16, 2000 -- Women over the age of 65 who are prescribed estrogen are more likely to have gallbladder or appendix removal surgery. This finding is from a study led by Dr. Muhammad Mamdani, Associate Scientist with the Institute for Clinical Evaluative Sciences (ICES) and Assistant Professor in the Faculty of Pharmacy, University of Toronto.
The study, published in the May 16th issue of the Canadian Medical Association Journal (CMAJ), tracked approximately 800,000 Ontario women over a five year period. Women on estrogen replacement were compared to control groups of women on other medications for the unrelated conditions of heart and thyroid disease.
The women on estrogen replacement were almost twice as likely to have had their gallbladders removed than were the other groups of women. The same increased rate of risk was noted for appendix removal.
"There still continues to be controversy about the benefits and risks of estrogen use in postmenopausal women. Our study is consistent with recent findings about the risks of this therapy that have gone largely unrecognized to this point," says Dr. Mamdani. Other recent studies have demonstrated a relationship between estrogen replacement therapy and abdominal pain, osteoarthritis and asthma. "The increased rate of gallbladder and appendix removal can be viewed as a marker for the less well-known physiologic effects of estrogen."
"The literature has shown that women who take estrogen replacement therapy tend to be healthier than those that don't, however this study points out that estrogen therapy may contribute to conditions associated with systemic inflammation or pain," says Dr. Mamdani.
ICES is a non-profit health services research organization dedicated to conducting research that contributes to the equity, effectiveness, quality and efficiency of health care in the province of Ontario.
The following study showing that women who smoke are not likely to show improvements in stopping osteoporosis may offer supportive evidence that estrogen increases the body accumulation of cadmium from tobacco smoke and that this cadmium interferes with bone growth, possibly by competing with copper.
Smoking, Low Body Weight, Risk Factors for Poor HRT ResponseA DGReview of :"Identification of Early Postmenopausal Women with No Bone Response to HRT: Results of a Five-Year Clinical Trial"
By Mark Greener
Hormone therapy raises thromboembolism risk for some women05/04/2000
By Anne MacLennan
Postmenopausal therapy with estrogen plus progestin puts women with coronary heart disease at increased risk for venous thromboembolism, a multi-centre study has found.
Authors of the study underline the need for doctors to be alert to this new finding when considering risks and benefits of hormone therapy for postmenopausal patients.
Conducted at 20 clinical centres in the United States, the study included 2,763 postmenopausal women whose average age was 67 years. (All were younger than 80 years.) All of the women had coronary heart disease but no previous venous thromboembolism (VTE). None had had a hysterectomy.
Over an average of 4.1 years follow-up, 34 of the women in the hormone therapy group and 13 on placebo had VTE events.
Analysis showed risk of VTE was increased in women with lower-extremity fractures or cancer and for 90 days after in-patient surgery or non-surgical hospitalization. Risk decreased with aspirin or statin use.
The group on hormone therapy -- 1,380 women -- received 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate, in one-tablet form. The other 1,383 women received look-alike placebo.
Outcome measures were documented deep venous thrombosis or pulmonary embolism.
Although oral contraceptive use is known to increase risk for VTE, this is one of few reports to date to document the effect of hormone therapy in women who are postmenopausal.
Annals of Internal Medicine, 2 May 2000.132:689-696.
The following study suggests the existence of a copper-tin compound with is involved in estrogen metabolism.
Premarin and Estrogens Decrease Thyroid Hormone in Women
Older women who are on both estrogen replacement and
thyroid replacement therapy may need a boost to the thyroid portion of their
regimen, new research suggests. Increased estrogen, according to one
investigator, can lower thyroid levels in some women being treated for
already-low concentrations of the hormone.
To be safe, women taking thyroid hormones should receive
check-ups within a few months of starting estrogen replacement.
The study was funded by
Knoll Pharmaceutical, which manufactures Synthroid™.
Thyroid hormone is used to treat hypothyroidism, a condition in which the body's levels of the hormone are too low. The thyroid gland acts like a barometer--churning out, as needed, hormones that help regulate a range of vital functions including
An underactive or non-functioning gland produces little or no thyroid hormone, triggering symptoms such as
Increases in estrogen, such as those that occur in pregnancy, lead to dips in thyroid levels. Among women with normal thyroid function, the gland can compensate and produce more thyroid hormone. But this barometer does not work in women with hypothyroidism.
The author recommends that women receiving both types of
hormone replacement have their thyroid levels checked within 12 weeks of
starting on estrogen--particularly women who are on thyroid hormone as part of
thyroid cancer treatment.
The New England Journal of
Medicine June 7, 2001; 344: 1743-1749, 1784-1785
DR. MERCOLA'S COMMENT:
Several issues are relevant here.
First off, traditional medicine has some serious
issues with their understanding of thyroid glandular replacements. Their
reliance on synthetic alternatives has caused unnecessary incredible grief and
suffering for millions of women.
So, even if the levels were monitored properly as
suggested, most women would be given higher doses of an inferior hormone.
Please note that the makers of Synthroid funded this article. They are
currently in a heap of trouble as Synthroid may be pulled from the market in
Secondly, most postmenopausal women do NOT need estrogen. In my view the only women who should be placed on estrogen are those who have their ovaries removed. If a woman still has functioning ovaries her body has the potential to produce estrogen in sufficient quantities if other factors are normalized.
JAMA published a landmark article this week on this
topic and I will post it next week.
As I said last year, if you still believe that
estrogen is good for you, you have been brain washed by the traditional media.
I would encourage you to review Dr. John Lee's excellent books on the topic. What
Your Doctor May Not Tell You About Premenopause : Balance Your Hormones and
Your Life from Thirty to Fifty
These companies will use every trick in the book to
get women to take these drugs which actually cause cancer. They tried to say
that estrogen reduced Alzheimer's, but a few years later the results showed
that it does not. The long held notion that estrogen reduces heart disease is
just plain untrue.
One of the classic arguments that traditional
medicine offers to convince women to begin or stay on estrogen therapy is
osteoporosis prevention, heart disease prevention, and more recently the hope
of prevention of Alzheimer's.
With 4 huge studies already showing no benefit, this avenue does not seem promising, at least with the synthetic progestin and horse-derived estrogen used. Maybe a more appropriate regimen of natural hormone replacement would show better results.
Hormone Replacement Therapy Linked to Breast Cancer
Adding to evidence that hormone replacement therapy (HRT) can potentially raise a woman's risk of breast cancer, a new US study links recent, long-term HRT with a heightened risk of the disease.
Researchers found that HRT with estrogen alone or estrogen-plus-progestin was associated with a 70% increase in breast cancer risk when the therapy was taken for 5 years within the 6 years preceding the cancer diagnosis.
The findings build on previous research showing a link between long-term HRT and breast cancer and help clear up the question of whether combination HRT and estrogen-only HRT carry similar risks.
In addition, the study of about 1,300 women found that HRT use had a particular link to lobular breast cancer, the form of the disease that begins in the breast's lobules. It is far less common than ductal breast cancer, which begins in the milk ducts.
Women who were recent, long-time users of HRT faced a three-fold risk of lobular cancer compared with women who never used HRT.
These women also had about a 50% increase in the risk of ductal cancer.
JAMA February 13, 2002;287:734-741
DR. MERCOLA'S COMMENT:
After all these years of estrogen hype it is becoming more and more clear to traditional medicine that the benefits of estrogen don't outweigh the risks.
So that leaves us with osteoporosis and hot flash relief.
It has been my experience that black cohosh works far more effectively for hot flash relief.
So that leaves us with osteoporosis. Well, a study published less than a year ago in JAMA showed that estrogen was not helpful to prevent against hip fractures.
Fortunately one can take vitamin D, K, omega three fats and plenty of vegetables and exercise to address osteoporosis.
One can only logically conclude that there is no reason for a woman to take hormone replacement therapy, unless her ovaries have been removed or she is interested in getting breast cancer.
It is important to make a distinction between women who have had their ovaries removed and those that have not. Those that have will likely benefit from low dose natural human estrogen replacement while those who still have ovaries will likely not.